Skip to main content

Table 3 Application of 2016 MAS classification criteria to patients with MAS treated with tocilizumab

From: Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

 

Tocilizumab

Historic cohort

Full-blown

Possible

All

Full-blown

Possible

All

Number with sufficient data

2

10

12

10

8

18

MAS (%, n)

50 (1/2)

20 (2/10)

25 (3/12)

90 (9/10)

75 (6/8)

83 (15/18)

Reasons missing (n)

Afebrile [1]

Afebrile [4]

 

Afebrile [1]

Other markers [2]

 

Ferritin [5]

  1. MAS Macrophage activation syndrome
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096